Oxidation reduces the fibrillation but not the neurotoxicity of the prion peptide PrP106-126

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1774, Issue 9, 2007, Pages 1118-1127

  Bergström, Ann Louise ^a   Chabry, Joëlle ^b   Bastholm, Lone ^c   Heegaard, Peter M H ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b CNRS   (France)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Apoptosis; Electroretinography; Oligomers; Oxidation; Prion peptide; Protofibrils

Indexed keywords

AMINO ACID; AMYLOID; METHIONINE; OLIGOMER; PRION PROTEIN; PROTEINASE K;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTRORETINOGRAPHY; FIBRIN FORMATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL CULTURE; NEUROTOXICITY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN VARIANT; REDUCTION;

AMYLOID; ANIMALS; CATTLE; CELL SURVIVAL; HUMANS; MALE; METHIONINE; MICE; MICE, INBRED C57BL; NEURONS; NEUROTOXINS; OXIDATION-REDUCTION; PEPTIDE FRAGMENTS; PRIONS;

BOVINAE; MUS;

EID: 34548317095     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2007.06.016     Document Type: Article

References (42)

1. Prusiner S.B. Molecular biology and pathogenesis of prion diseases. Trends Biochem. Sci. 21 (1996) 482-487
2. Prusiner S.B. Prion diseases of humans and animals (1992), Ellis Horwood Limited
3. Tagliavini F., Prelli F., Verga L., Giaccone G., Sarma R., Gorevic P., Ghetti B., Passerini F., Ghibaudi E., and Forloni G. Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 9678-9682
4. Ettaiche M., Pichot R., Vincent J.P., and Chabry J. In vivo cytotoxicity of the prion protein fragment 106-126. J. Biol. Chem. 275 (2000) 36487-36490
5. Forloni G., Angeretti N., Chiesa R., Monzani E., Salmona M., Bugiani O., and Tagliavini F. Neurotoxicity of a prion protein fragment. Nature 362 (1993) 543-546
6. Salmona M., Malesani P., De Gioia L., Gorla S., Bruschi M., Molinari A., Della V.F., Pedrotti B., Marrari M.A., Awan T., Bugiani O., Forloni G., and Tagliavini F. Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. Biochem. J. 342 Pt 1 (1999) 207-214
7. Florio T., Paludi D., Villa V., Principe D.R., Corsaro A., Millo E., Damonte G., D'Arrigo C., Russo C., Schettini G., and Aceto A. Contribution of two conserved glycine residues to fibrillogenesis of the 106-126 prion protein fragment. Evidence that a soluble variant of the 106-126 peptide is neurotoxic. J. Neurochem. 85 (2003) 62-72
8. Brown D.R., Schmidt B., and Kretzschmar H.A. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature 380 (1996) 345-347
9. Kretzschmar H.A., Giese A., Brown D.R., Herms J., Keller B., Schmidt B., and Groschup M. Cell death in prion disease. J. Neural Transm., Suppl. 50 (1997) 191-210
10. Chabry J., Ratsimanohatra C., Sponne I., Elena P.P., Vincent J.P., and Pillot T. In vivo and in vitro neurotoxicity of the human prion protein (PrP) fragment P118-135 independently of PrP expression. J. Neurosci. 23 (2003) 462-469
11. Collinge J., Owen F., Poulter M., Leach M., Crow T.J., Rossor M.N., Hardy J., Mullan M.J., Janota I., and Lantos P.L. Prion dementia without characteristic pathology. Lancet 336 (1990) 7-9
12. Lasmezas C.I., Deslys J.P., Robain O., Jaegly A., Beringue V., Peyrin J.M., Fournier J.G., Hauw J.J., Rossier J., and Dormont D. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 275 (1997) 402-405
13. Mahadevan A., Shankar S.K., Yasha T.C., Santosh V., Sarkar C., Desai A.P., and Satishchandra P. Brain biopsy in Creutzfeldt-Jakob disease: evolution of pathological changes by prion protein immunohistochemistry. Neuropathol. Appl. Neurobiol. 28 (2002) 314-324
14. Kayed R., Sokolov Y., Edmonds B., McIntire T.M., Milton S.C., Hall J.E., and Glabe C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279 (2004) 46363-46366
15. Masel J., Genoud N., and Aguzzi A. Efficient inhibition of prion replication by PrP-Fc(2) suggests that the prion is a PrP(Sc) oligomer. J. Mol. Biol. 345 (2005) 1243-1251
16. Novitskaya V., Bocharova O.V., Bronstein I., and Baskakov I.V. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. Chem. 281 (2006) 13828-13836
17. Rosenblum W.I. Structure and location of amyloid beta peptide chains and arrays in Alzheimer's disease: new findings require reevaluation of the amyloid hypothesis and of tests of the hypothesis. Neurobiol. Aging 23 (2002) 225-230
18. Chromy B.A., Nowak R.J., Lambert M.P., Viola K.L., Chang L., Velasco P.T., Jones B.W., Fernandez S.J., Lacor P.N., Horowitz P., Finch C.E., Krafft G.A., and Klein W.L. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42 (2003) 12749-12760
19. Walsh D.M., and Selkoe D.J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 11 (2004) 213-228
20. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., and Lansbury Jr. P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 571-576
21. Cole N.B., Murphy D.D., Lebowitz J., Di Noto L., Levine R.L., and Nussbaum R.L. Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. J. Biol. Chem. 280 (2005) 9678-9690
22. Hokenson M.J., Uversky V.N., Goers J., Yamin G., Munishkina L.A., and Fink A.L. Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein. Biochemistry 43 (2004) 4621-4633
23. Lin M.T., and Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 (2006) 787-795
24. Butterfield D.A. Oxidative stress in neurodegenerative disorders. Antioxid. Redox Signal. 8 (2006) 1971-1973
25. Requena J.R., Dimitrova M.N., Legname G., Teijeira S., Prusiner S.B., and Levine R.L. Oxidation of methionine residues in the prion protein by hydrogen peroxide. Arch. Biochem. Biophys. 432 (2004) 188-195
26. Requena J.R., Groth D., Legname G., Stadtman E.R., Prusiner S.B., and Levine R.L. Copper-catalyzed oxidation of the recombinant SHa(29-231) prion protein. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 7170-7175
27. Wong B.S., Wang H., Brown D.R., and Jones I.M. Selective oxidation of methionine residues in prion proteins. Biochem. Biophys. Res. Commun. 259 (1999) 352-355
28. Heegaard P.M., Pedersen H.G., Flink J., and Boas U. Amyloid aggregates of the prion peptide PrP106-126 are destabilised by oxidation and by the action of dendrimers. FEBS Lett. 577 (2004) 127-133
29. Watson A.A., Fairlie D.P., and Craik D.J. Solution structure of methionine-oxidized amyloid beta-peptide (1-40). Does oxidation affect conformational switching?. Biochemistry 37 (1998) 12700-12706
30. Uversky V.N., Yamin G., Souillac P.O., Goers J., Glaser C.B., and Fink A.L. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett. 517 (2002) 239-244
31. Barnham K.J., Ciccotosto G.D., Tickler A.K., Ali F.E., Smith D.G., Williamson N.A., Lam Y.H., Carrington D., Tew D., Kocak G., Volitakis I., Separovic F., Barrow C.J., Wade J.D., Masters C.L., Cherny R.A., Curtain C.C., Bush A.I., and Cappai R. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 278 (2003) 42959-42965
32. Vaughan-Thomas A., Gilbert S.J., and Duance V.C. Elevated levels of proteolytic enzymes in the aging human vitreous. Investig. Ophthalmol. Vis. Sci. 41 (2000) 3299-3304
33. Bergstrom A.L., Cordes H., Zsurger N., Heegaard P.M., Laursen H., and Chabry J. Amidation and structure relaxation abolish the neurotoxicity of the prion peptide PrP106-126 in vivo and in vitro. J. Biol. Chem. 280 (2005) 23114-23121
34. Bueler H., Fischer M., Lang Y., Bluethmann H., Lipp H.P., DeArmond S.J., Prusiner S.B., Aguet M., and Weissmann C. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356 (1992) 577-582
35. Lehmann S., and Grassi J. Techniques in Prion Research (2004), Birkhäuser
36. Hope J., Shearman M.S., Baxter H.C., Chong A., Kelly S.M., and Price N.C. Cytotoxicity of prion protein peptide (PrP106-126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25-35. Neurodegeneration 5 (1996) 1-11
37. Jobling M.F., Stewart L.R., White A.R., McLean C., Friedhuber A., Maher F., Beyreuther K., Masters C.L., Barrow C.J., Collins S.J., and Cappai R. The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106-126. J. Neurochem. vol. 73 (1999) 1557-1565
38. Kovacs G.G., Head M.W., Bunn T., Laszlo L., Will R.G., and Ironside J.W. Clinicopathological phenotype of codon 129 valine homozygote sporadic Creutzfeldt-Jakob disease. Neuropathol. Appl. Neurobiol. 26 (2000) 463-472
39. Kovacs G.G., Trabattoni G., Hainfellner J.A., Ironside J.W., Knight R.S., and Budka H. Mutations of the prion protein gene phenotypic spectrum. J. Neurol. 249 (2002) 1567-1582
40. Brown D.R. Prion protein peptides: optimal toxicity and peptide blockade of toxicity. Mol. Cell. Neurosci. 15 (2000) 66-78
41. Kuwata K., Matumoto T., Cheng H., Nagayama K., James T.L., and Roder H. NMR-detected hydrogen exchange and molecular dynamics simulations provide structural insight into fibril formation of prion protein fragment 106-126. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14790-14795
42. Villa V., Corsaro A., Thellung S., Paludi D., Chiovitti K., Venezia V., Nizzari M., Russo C., Schettini G., Aceto A., and Florio T. Characterization of the proapoptotic intracellular mechanisms induced by a toxic conformer of the recombinant human prion protein fragment 90-231. Ann. N.Y. Acad. Sci. 1090 (2006) 276-291